Gilead Sciences Inc
GILD103.170USD
-2.980-2.81%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
128.55BMarktkapitalisierung
267.81KGV TTM
mehr Informationen über Gilead Sciences Inc Unternehmen
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.
Unternehmensinformationen
Unternehmens-codeGILD
Name des UnternehmensGilead Sciences Inc
IPO-datumJan 22, 1992
Gegründet am1987
CEOMr. Daniel P. O'Day
Anzahl der mitarbeiter17600
WertpapierartOrdinary Share
GeschäftsjahresendeJan 22
Addresse333 Lakeside Dr
StadtFOSTER CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94404-1147
Telefon16505743000
Websitehttps://www.gilead.com/
Unternehmens-codeGILD
IPO-datumJan 22, 1992
Gegründet am1987
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
96.93K
+4.50%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
24.54K
--
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
19.55K
+12.77%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
10.23K
--
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
96.93K
+4.50%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
24.54K
--
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
19.55K
+12.77%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
10.23K
--
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biktarvy
13.42B
46.69%
Descovy
2.11B
7.35%
Genvoya
1.76B
6.13%
Sofosbuvir/Velpatasvir
1.59B
5.55%
Yescarta
1.57B
5.46%
Other
8.29B
28.83%
Nach RegionUSD
Name
Umsatz
Anteil
United States
19.51B
67.84%
Europe
4.35B
15.12%
Other Locations
2.91B
10.11%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biktarvy
13.42B
46.69%
Descovy
2.11B
7.35%
Genvoya
1.76B
6.13%
Sofosbuvir/Velpatasvir
1.59B
5.55%
Yescarta
1.57B
5.46%
Other
8.29B
28.83%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.23%
BlackRock Institutional Trust Company, N.A.
5.98%
Capital World Investors
5.76%
State Street Global Advisors (US)
4.85%
Capital Research Global Investors
4.65%
Other
69.52%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.23%
BlackRock Institutional Trust Company, N.A.
5.98%
Capital World Investors
5.76%
State Street Global Advisors (US)
4.85%
Capital Research Global Investors
4.65%
Other
69.52%
Art
Aktionäre
Anteil
Investment Advisor
42.74%
Investment Advisor/Hedge Fund
35.47%
Research Firm
3.17%
Pension Fund
2.96%
Sovereign Wealth Fund
1.74%
Bank and Trust
1.71%
Hedge Fund
1.60%
Insurance Company
0.15%
Individual Investor
0.08%
Other
10.38%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
3240
1.12B
90.10%
+6.51M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
2023Q1
3195
1.09B
87.26%
-11.17M
2022Q4
3203
1.08B
86.64%
+1.09M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
114.97M
9.22%
+203.25K
+0.18%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
74.47M
5.97%
-1.75M
-2.30%
Dec 31, 2024
Capital World Investors
71.71M
5.75%
-4.84M
-6.33%
Dec 31, 2024
State Street Global Advisors (US)
60.38M
4.84%
+210.06K
+0.35%
Dec 31, 2024
Capital Research Global Investors
57.95M
4.65%
-3.85M
-6.24%
Dec 31, 2024
Wellington Management Company, LLP
35.66M
2.86%
+1.06M
+3.06%
Dec 31, 2024
Fidelity Management & Research Company LLC
34.64M
2.78%
+6.42M
+22.73%
Dec 31, 2024
Dodge & Cox
32.95M
2.64%
-98.02K
-0.30%
Dec 31, 2024
Geode Capital Management, L.L.C.
28.29M
2.27%
+749.05K
+2.72%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
25.78M
2.07%
+346.10K
+1.36%
Feb 28, 2025
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
VanEck Biotech ETF
12%
Invesco Nasdaq Biotechnology ETF
10.22%
ProShares Ultra Nasdaq Biotechnology
7.84%
iShares Biotechnology ETF
7.01%
Invesco Biotechnology & Genome ETF
6.3%
First Trust NASDAQ Pharmaceuticals ETF
6.11%
VanEck Morningstar Wide Moat Value ETF
5.8%
Global X US Cash Flow Kings 100 ETF
5.67%
Simplify Health Care ETF
4.99%
USCF Dividend Income Fund
4.95%
Mehr Anzeigen
VanEck Biotech ETF
Anteil12%
Invesco Nasdaq Biotechnology ETF
Anteil10.22%
ProShares Ultra Nasdaq Biotechnology
Anteil7.84%
iShares Biotechnology ETF
Anteil7.01%
Invesco Biotechnology & Genome ETF
Anteil6.3%
First Trust NASDAQ Pharmaceuticals ETF
Anteil6.11%
VanEck Morningstar Wide Moat Value ETF
Anteil5.8%
Global X US Cash Flow Kings 100 ETF
Anteil5.67%
Simplify Health Care ETF
Anteil4.99%
USCF Dividend Income Fund
Anteil4.95%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
18.49B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
Apr 28, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jun 29, 2023
Jun 14, 2023
Feb 02, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Mar 30, 2023
Mar 14, 2023
Oct 27, 2022
GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022
Dec 15, 2022
Dec 29, 2022
Dec 14, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten